<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Inflammatory</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Hematopoietic stem cell research points to leukemia’s early roots</title>
      <description>
        <![CDATA[Hematopoietic stem cell research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and inflammation, then, may hold the keys to preventing blood cancers, according to John E. Dick’s plenary session at the 2026 Korean Society of Hematology International Conference, held March 26, 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730162</guid>
      <pubDate>Thu, 02 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730162-hematopoietic-stem-cell-research-points-to-leukemias-early-roots</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cells.webp?t=1588880225" type="image/png" medium="image" fileSize="554020">
        <media:title type="plain">Cancer and blood cells</media:title>
      </media:content>
    </item>
    <item>
      <title>Five-drug VIPOR regimen shows promise in aggressive blood cancer </title>
      <description>
        <![CDATA[Deep molecular advances are enabling precision medicine for the field of hematology, Wyndham Wilson said during a plenary session at the 2026 Korean Society of Hematology International Conference March 26.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729980</guid>
      <pubDate>Wed, 01 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729980-five-drug-vipor-regimen-shows-promise-in-aggressive-blood-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/ICKSH_ViPOR-scans-4-1.webp?t=1775073716" type="image/jpeg" medium="image" fileSize="427849">
        <media:title type="plain">PET scans showing before and after treatment with VIPOR</media:title>
        <media:description type="plain">Before (top) and after (bottom) treatment with VIPOR. Full-body and cross-sectional PET scans of a patient show large lymphoma tumors (circled in red) that have disappeared with treatment. Credit: Center for Cancer Research/National Cancer Institute</media:description>
      </media:content>
    </item>
    <item>
      <title>US FDA warns of liver injuries, 8 deaths associated with Tavneos </title>
      <description>
        <![CDATA[Once again, Amgen Inc.’s Tavneos (avacopan) is under U.S. FDA scrutiny, as the agency alerted patients and doctors March 31 about 76 cases of drug-induced liver injury, including eight deaths, with “reasonable evidence of a causal association” with the drug.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729978</guid>
      <pubDate>Wed, 01 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729978-us-fda-warns-of-liver-injuries-8-deaths-associated-with-tavneos</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-on-digital-lens.webp?t=1709588066" type="image/jpeg" medium="image" fileSize="175206">
        <media:title type="plain">Liver over digital lens background</media:title>
      </media:content>
    </item>
    <item>
      <title>Hematopoietic stem cell research points to leukemia’s early roots</title>
      <description>
        <![CDATA[Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and inflammation, then, may hold the keys to preventing blood cancers, according to John E. Dick’s plenary session at the 2026 Korean Society of Hematology International Conference (ICKSH 2026), held March 26, 2026. Work in Dick’s lab has found acute myeloid leukemia (AML) HSCs that harbor preleukemic mutations long before any disease diagnosis. These insights have enabled predictive models that could identify individuals at elevated AML risk years before the onset of outright disease, opening the door to new prevention strategies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730055</guid>
      <pubDate>Wed, 01 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730055-hematopoietic-stem-cell-research-points-to-leukemias-early-roots</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cells.webp?t=1588880225" type="image/png" medium="image" fileSize="554020">
        <media:title type="plain">Cancer and blood cells</media:title>
      </media:content>
    </item>
    <item>
      <title>Galapagos enters new era as Lakefront after reshaping Gilead alliance</title>
      <description>
        <![CDATA[Galapagos NV is about to bury its recent turbulent past and sail off for the future with its $3 billion cash pile and the new name of Lakefront Biotherapeutics NV. The foundation for the transition was laid earlier this month in an arrangement with Gilead Sciences Inc., holder of 25% of Galapagos’ equity, to “co-parent” the assets of Ouro Medicines LLC, which Gilead is acquiring for up to $2.17 billion.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729964</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729964-galapagos-enters-new-era-as-lakefront-after-reshaping-gilead-alliance</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Handshake-icon-on-hexagonal-background.webp?t=1774991990" type="image/jpeg" medium="image" fileSize="848145">
        <media:title type="plain">Handshake icon engraved on metal hexagonal background</media:title>
      </media:content>
    </item>
    <item>
      <title>Sichuan Kelun-Biotech identifies new glucocorticoid receptor agonists</title>
      <description>
        <![CDATA[Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has discovered new glucocorticoid receptor (GR) agonists potentially useful for the treatment of rheumatoid arthritis, idiopathic arthritis, systemic lupus erythematosus, asthma, ulcerative colitis, neuromyelitis optica and autoimmune liver disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730029</guid>
      <pubDate>Mon, 30 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730029-sichuan-kelun-biotech-identifies-new-glucocorticoid-receptor-agonists</link>
    </item>
    <item>
      <title>Ventus Therapeutics patents caspase-4/5 inhibitors</title>
      <description>
        <![CDATA[Work at Ventus Therapeutics US Inc. has led to the identification of new caspase-4 allosteric and/or caspase-5 inhibitors reported to be useful for the treatment of sepsis, stroke, myocardial infarction, acute respiratory distress syndrome, inflammatory bowel disease, hidradenitis suppurativa, diabetic nephropathy and diabetic retinopathy, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730027</guid>
      <pubDate>Mon, 30 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730027-ventus-therapeutics-patents-caspase-4-5-inhibitors</link>
    </item>
    <item>
      <title>Rapt Therapeutics synthesizes new TNF-α modulators</title>
      <description>
        <![CDATA[Rapt Therapeutics Inc. has patented new fused ring imidazole compounds acting as TNF-α modulators and thus reported to be useful for the treatment of cancer, pain, metabolic and autoimmune disease, inflammation, neurological, cardiovascular and eyes disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730026</guid>
      <pubDate>Mon, 30 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730026-rapt-therapeutics-synthesizes-new-tnf-modulators</link>
    </item>
    <item>
      <title>Molecular signatures show subtypes in neurodegenerative diseases</title>
      <description>
        <![CDATA[Parkinson’s disease is a progressive neurodegenerative disorder best known for its motor symptoms. However, a proportion of patients also develop dementia as the condition advances. Yet the biological divide between those who experience this cognitive decline and those who do not has remained an open question. Are they different conditions or simply stages of the same disease?]]>
      </description>
      <guid>http://www.bioworld.com/articles/730013</guid>
      <pubDate>Mon, 30 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730013-molecular-signatures-show-subtypes-in-neurodegenerative-diseases</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Neuron-nerve-cell-dna-genetics.webp?t=1774882830" type="image/jpeg" medium="image" fileSize="414335">
        <media:title type="plain">Illustration of a nerve cell with DNA double helix</media:title>
      </media:content>
    </item>
    <item>
      <title>Multibody TEV‘325 achieves preclinical milestone</title>
      <description>
        <![CDATA[Biolojic Design Ltd. has earned an additional milestone payment from its collaboration partner, Teva Pharmaceutical Industries Ltd., for TEV‘325 (TEV-56308, formerly BD-9), a multibody targeting IL-13 and thymic stromal lymphopoietin (TSLP) for autoimmune disease]]>
      </description>
      <guid>http://www.bioworld.com/articles/729930</guid>
      <pubDate>Thu, 26 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729930-multibody-tev325-achieves-preclinical-milestone</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/collaboration-research-milestones-illustration.webp?t=1735313933" type="image/jpeg" medium="image" fileSize="78720">
        <media:title type="plain">Illustration of a road with three destination markers</media:title>
      </media:content>
    </item>
    <item>
      <title>Gilead pens dual-purpose $2B Ouro M&amp;A deal with Galapagos </title>
      <description>
        <![CDATA[Gilead Sciences Inc. said after U.S. market close March 23 that it will acquire privately held Ouro Medicines LLC and its autoimmune BCMA/CD3 bispecific T-cell engager, gamgertamig, in a deal valued at $2.17 billion.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729829</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729829-gilead-pens-dual-purpose-2b-ouro-m-and-a-deal-with-galapagos</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Hands-and-gears.webp?t=1590606316" type="image/png" medium="image" fileSize="377385">
        <media:title type="plain">Hands holding gears</media:title>
      </media:content>
    </item>
    <item>
      <title>Somatic genomics pioneer Quotient signs $2.2B IBD deal with Merck</title>
      <description>
        <![CDATA[For a company founded only four years ago, Quotient Therapeutics Inc. entered its third major deal, this time with Merck & Co. Inc. to find novel drug targets for inflammatory bowel disease (IBD) using its somatic genomics platform technology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729823</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729823-somatic-genomics-pioneer-quotient-signs-22b-ibd-deal-with-merck</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/GI-system-with-DNA-scientific-background.webp?t=1774388477" type="image/jpeg" medium="image" fileSize="500606">
        <media:title type="plain">Gastrointestinal system with DNA, scientific background</media:title>
      </media:content>
    </item>
    <item>
      <title>Qilu Pharma describes new VAV1 degradation inducers</title>
      <description>
        <![CDATA[Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has prepared and tested molecular glue degraders comprising E3 ubiquitin-protein ligases acting as proto-oncogene Vav (VAV1) degradation inducers reported to be useful for the treatment of inflammation and autoimmune diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729869</guid>
      <pubDate>Tue, 24 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729869-qilu-pharma-describes-new-vav1-degradation-inducers</link>
    </item>
    <item>
      <title>Apex Biosciences presents new phosphodiesterase inhibitors</title>
      <description>
        <![CDATA[Apex Biosciences Pte. Ltd. has identified phosphodiesterase (PDE) inhibitors reported to be useful for the treatment of arthritis, coronary artery diseases, idiopathic pulmonary fibrosis, inflammatory bowel disease, metabolic dysfunction-associated steatohepatitis, neurodegeneration, obstructive sleep apnea and cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729865</guid>
      <pubDate>Tue, 24 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729865-apex-biosciences-presents-new-phosphodiesterase-inhibitors</link>
    </item>
    <item>
      <title>ADPD 2026: Three inflection points to target Alzheimer’s disease</title>
      <description>
        <![CDATA[A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change how new drugs are developed to achieve more effective therapies. This new perspective could rethink strategies that depend not so much on the target itself, but on the precise moment at which it is addressed.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729852</guid>
      <pubDate>Fri, 20 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729852-adpd-2026-three-inflection-points-to-target-alzheimers-disease</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Alzheimers-disease-neurons-illustration.webp?t=1773932679" type="image/jpeg" medium="image" fileSize="319204">
        <media:title type="plain">Illustration of Alzheimer's disease in the brain</media:title>
      </media:content>
    </item>
    <item>
      <title>NOX4 inhibitors divulged in Boehringer Ingelheim patent</title>
      <description>
        <![CDATA[Work at Boehringer Ingelheim Pharma GmbH & Co. KG has led to the synthesis of pyrazolo[5,1-<em>f</em>][1,2,4]triazin-4-ones acting as NADPH oxidase 4 (NOX4) inhibitors. As such, they are described as potentially useful for the treatment of liver disease, portal hypertension, viral infection, cancer, interstitial lung diseases, retinopathy, inflammation and fibrosis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729735</guid>
      <pubDate>Thu, 19 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729735-nox4-inhibitors-divulged-in-boehringer-ingelheim-patent</link>
    </item>
    <item>
      <title>circPTK2 unveiled as a driver of pulmonary fibrosis</title>
      <description>
        <![CDATA[Pulmonary fibrosis (PF) is a fatal lung disease characterized by excessive deposition of extracellular matrix proteins in the lung interstitium due to excessive fibroblast activation, which leads to tissue scarring and potential respiratory failure. Chinese researchers have published results of their investigations into circular RNAs and the pathogenesis of PF.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729725</guid>
      <pubDate>Thu, 19 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729725-circptk2-unveiled-as-a-driver-of-pulmonary-fibrosis</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Respiratory-lungs-inflammation.webp?t=1698075497" type="image/jpeg" medium="image" fileSize="261810">
        <media:title type="plain">AI generated illustration of lungs in the human body</media:title>
      </media:content>
    </item>
    <item>
      <title>ADPD 2026: Three inflection points to target Alzheimer’s disease</title>
      <description>
        <![CDATA[A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change how new drugs are developed to achieve more effective therapies. This new perspective could rethink strategies that depend not so much on the target itself, but on the precise moment at which it is addressed.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729719</guid>
      <pubDate>Thu, 19 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729719-adpd-2026-three-inflection-points-to-target-alzheimers-disease</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Alzheimers-disease-neurons-illustration.webp?t=1773932679" type="image/jpeg" medium="image" fileSize="319204">
        <media:title type="plain">Illustration of Alzheimer's disease in the brain</media:title>
      </media:content>
    </item>
    <item>
      <title>ADPD 2026: Can we prevent dementia? Scientists quantify it</title>
      <description>
        <![CDATA[Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated microglia and astrocytes, altered receptors such as TREM2, mitochondrial dysfunction, epigenetic changes and cerebrovascular alterations all seem to contribute to the development of dementia in Alzheimer’s disease (AD). While scientists attempt to address each of these elements, prevention is growing as a primary goal.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729688</guid>
      <pubDate>Wed, 18 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729688-adpd-2026-can-we-prevent-dementia-scientists-quantify-it</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Neurology-brain-MRI-imaging.webp?t=1773844698" type="image/jpeg" medium="image" fileSize="977275">
        <media:title type="plain">MRI image brain on black background</media:title>
      </media:content>
    </item>
    <item>
      <title>China’s Qyuns moves IL-17 biologic toward first approval</title>
      <description>
        <![CDATA[Qyuns Therapeutics Co. Ltd. has moved closer to its first commercial product after China’s National Medical Products Administration (NMPA) accepted its NDA for IL-17 antibody crusekitug (QX-002N) for treating ankylosing spondylitis (AS), a chronic inflammatory disease that affects the spine and sacroiliac joints.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729710</guid>
      <pubDate>Tue, 17 Mar 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729710-chinas-qyuns-moves-il-17-biologic-toward-first-approval</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Musculoskeletal/Inflamed-Lumbar-Spine-Disc.webp?t=1773260221" type="image/jpeg" medium="image" fileSize="666699">
        <media:title type="plain">Illustration of inflamed spine</media:title>
      </media:content>
    </item>
    <item>
      <title>Enodia jumps ahead in Sec61 targeting, adds Kezar’s program</title>
      <description>
        <![CDATA[Enodia Therapeutics Inc. was spun out of The Institut Pasteur by Argobio Studio based on the work of Caroline Demangel, co-founder of Enodia and head of the immunobiology and therapy unit at The Institut Pasteur. Demangel’s lab discovered the mechanism of action of mycolactone, a natural Sec61 inhibitor that causes Buruli ulcers.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729706</guid>
      <pubDate>Tue, 17 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729706-enodia-jumps-ahead-in-sec61-targeting-adds-kezars-program</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Tinted-Euro-symbol.webp?t=1685996236" type="image/jpeg" medium="image" fileSize="59509">
        <media:title type="plain">Tinted Euro symbol</media:title>
      </media:content>
    </item>
    <item>
      <title>Mestag raises $40M to take fibroblast program into phase I cancer trial</title>
      <description>
        <![CDATA[Mestag Therapeutics Ltd. has raised a $40 million round from existing investors as it completes final preparations for its lead program MST-0312 to enter clinical development in mid-2026. MST-0312 is a bispecific antibody aimed at the lymphotoxin-β receptor (LTBR), which is essential for the development of lymphoid tissues.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729707</guid>
      <pubDate>Tue, 17 Mar 2026 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729707-mestag-raises-40m-to-take-fibroblast-program-into-phase-i-cancer-trial</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Fibroblast-cell-blue-illustration.webp?t=1750171818" type="image/jpeg" medium="image" fileSize="667579">
        <media:title type="plain">Fibroblast illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Enodia jumps ahead in Sec61 targeting, adds Kezar’s program</title>
      <description>
        <![CDATA[Enodia Therapeutics Inc. was spun out of The Institut Pasteur by Argobio Studio based on the work of Caroline Demangel, co-founder of Enodia and head of the immunobiology and therapy unit at The Institut Pasteur. Demangel’s lab discovered the mechanism of action of mycolactone, a natural Sec61 inhibitor that causes Buruli ulcers.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729529</guid>
      <pubDate>Mon, 16 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729529-enodia-jumps-ahead-in-sec61-targeting-adds-kezars-program</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Tinted-Euro-symbol.webp?t=1685996236" type="image/jpeg" medium="image" fileSize="59509">
        <media:title type="plain">Tinted Euro symbol</media:title>
      </media:content>
    </item>
    <item>
      <title>Synnovation Therapeutics synthesizes TNF-α inhibitors</title>
      <description>
        <![CDATA[Synnovation Therapeutics Inc. has discovered heterocyclic TNF-α inhibitors designed for use in the treatment of inflammatory disorders and neurodegeneration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729659</guid>
      <pubDate>Mon, 16 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729659-synnovation-therapeutics-synthesizes-tnf-inhibitors</link>
    </item>
    <item>
      <title>Foshan Ionova Biotherapeutics and collaborators identify IL-17A inhibitors</title>
      <description>
        <![CDATA[Foshan Ionova Biotherapeutics Co. Ltd., Guangdong Touchstone Translational Research Institute Co. Ltd. and Shenzhen Ionova Life Science Co. Ltd. have synthesized new interleukin-17A (IL-17A) inhibitors described as potentially useful for the treatment of inflammatory disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729637</guid>
      <pubDate>Fri, 13 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729637-foshan-ionova-biotherapeutics-and-collaborators-identify-il-17a-inhibitors</link>
    </item>
    <item>
      <title>Baseimmune expands into fibrosis</title>
      <description>
        <![CDATA[Baseimmune Ltd. has announced its strategic expansion into fibrosis, with a new fibrosis-focused pipeline led by a program for idiopathic pulmonary fibrosis (IPF). ]]>
      </description>
      <guid>http://www.bioworld.com/articles/729607</guid>
      <pubDate>Thu, 12 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729607-baseimmune-expands-into-fibrosis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Respiratory/Respiratory-lung-alveoli.webp?t=1745266926" type="image/jpeg" medium="image" fileSize="332757">
        <media:title type="plain">Illustration of alveoli and lungs</media:title>
      </media:content>
    </item>
    <item>
      <title>China’s Qyuns moves IL-17 biologic toward first approval</title>
      <description>
        <![CDATA[Qyuns Therapeutics Co. Ltd. has moved closer to its first commercial product after China’s National Medical Products Administration (NMPA) accepted its NDA for IL-17 antibody crusekitug (QX-002N) for treating ankylosing spondylitis (AS), a chronic inflammatory disease that affects the spine and sacroiliac joints.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729467</guid>
      <pubDate>Wed, 11 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729467-chinas-qyuns-moves-il-17-biologic-toward-first-approval</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Musculoskeletal/Inflamed-Lumbar-Spine-Disc.webp?t=1773260221" type="image/jpeg" medium="image" fileSize="666699">
        <media:title type="plain">Illustration of inflamed spine</media:title>
      </media:content>
    </item>
    <item>
      <title>HX-16108 holds promise for treating inflammatory skin diseases</title>
      <description>
        <![CDATA[Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has developed a bispecific antibody targeting both IL-13 and IL-31, HX-16108, with an extended half-life.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729592</guid>
      <pubDate>Wed, 11 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729592-hx-16108-holds-promise-for-treating-inflammatory-skin-diseases</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Dermatologic-atopic-dermatitis2.webp?t=1588881560" type="image/png" medium="image" fileSize="357317">
        <media:title type="plain">Skin irritation on hands</media:title>
      </media:content>
    </item>
    <item>
      <title>Earendil’s HXN‑1021 exhibits potent, extended OX40L targeting</title>
      <description>
        <![CDATA[The signaling axis orchestrated by OX40L-OX40 is a T-cell costimulatory pathway implicated in multiple autoimmune diseases, such as atopic dermatitis (AD). Antibodies targeting this pathway have proven useful at treating AD in the clinical setting. Earendil Labs recently presented data regarding HXN-1021, an anti-OX40L antibody with potent activity and extended half-life, in vivo.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729511</guid>
      <pubDate>Tue, 10 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729511-earendils-hxn1021-exhibits-potent-extended-ox40l-targeting</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Inflammatory-tissue-inflammation.webp?t=1684247889" type="image/jpeg" medium="image" fileSize="336115">
        <media:title type="plain">Art concept for inflamed human tissue</media:title>
      </media:content>
    </item>
    <item>
      <title>Hangzhou Innogate and Innorace divulge MRGPRX2 antagonists</title>
      <description>
        <![CDATA[Hangzhou Innogate Pharma Co. Ltd. and Innorace Biopharma Co. Ltd. have patented new Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists designed for use in the treatment of atopic dermatitis, irritable bowel syndrome, metabolic syndrome, migraine, pain, neuropathic pain, rheumatoid arthritis and urticaria, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729385</guid>
      <pubDate>Thu, 05 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729385-hangzhou-innogate-and-innorace-divulge-mrgprx2-antagonists</link>
    </item>
  </channel>
</rss>
